Business, Drugs and Pharmaceuticals, Free News Articles

Kalyagen Announces Attendance and Speaking Engagement at 8th Annual Biohacking Conference

AUSTIN, Texas -- Kalyagen is pleased to announce that it will be attending and its founder, Christian Drapeau, will be speaking at the upcoming 8th Annual Biohacking Conference. The conference, which is completely sold out, will be held September 15-17 at The Beverly Hilton in Beverly Hills, California.

"The Biohacking Conference will be an ideal opportunity to introduce STEMREGEN directly to an audience whose core focus is to tap into the body's innate ability to repair," said Christian Drapeau. "We are eager to meet and collaborate with the leaders of the biohacking movement."

STEMREGEN® is a unique and patent-pending blend of proprietary plant-based extracts documented to increase the number of circulating stem cells by stimulating Endogenous Stem Cell Mobilization (ESCM). Ingredients in STEMREGEN® have been investigated in more than eight studies for their effect on stem cell function, of which five were randomized, double-blind, placebo-controlled human clinical trials. STEMREGEN® has wide application in anti-aging and overall health maintenance.

"The link between a lower number of circulating stem cells and the development of age-related diseases has been well studied with numerous degenerative conditions, including diabetes, cardiovascular diseases, atherosclerosis, Alzheimer's disease, rheumatoid arthritis, pulmonary diseases, erectile dysfunction, and kidney disease," continued Mr. Drapeau. "From a therapeutic standpoint, increasing the number of circulating stem cells has been documented to enhance tissue repair or improve the course of disease formation in many degenerative conditions and overall health and well-being."

About Kalyagen:

Austin-based Kalyagen® was founded by Christian Drapeau, author of the bestseller Cracking the Stem Cell Code. Kalyagen® is a leader in the research and development of natural products aimed at supporting stem cell function of the body. Stem cells constitute the natural repair system of the body, and stem cell enhancers have been documented to strongly contribute to improving health and quality of life. STEMREGEN® is the first stem cell enhancer product developed by Kalyagen®. STEMREGEN® is a unique blend of proprietary plant-based extracts documented to support Endogenous Stem Cell Mobilization and provide other health benefits.

For more information, please visit our website: https://www.kalyagen.com/

CONTACT:

Biomics, LLC (dba Kalyagen®)

Herbert Dogan, Chief Marketing Officer (310-433-8072)

hgd@kalyagen.com

Social media: @kalyagen #kalyagen #christiandrapeau #stemcellchristian #stemregen #stemcells #stemregeneffect #stemthetideoftime #stemthetide #biohacking

Disclaimer: None of the statements contained in this press release have been evaluated by the U.S. Food and Drug Administration. The products and information in the release are not intended to diagnose, treat, cure or prevent any disease.

Related link: https://www.kalyagen.com/

This news story was published by the Neotrope® News Network - all rights reserved. ID:NEO2022

Business, Drugs and Pharmaceuticals, Free News Articles, Product Launches

Zeteo Biomedical Introduces OrionMRQ™ Nasal Delivery Device for Vaccines

PFLUGERVILLE, Texas -- Zeteo Biomedical LLC announced today the availability of the ZEOx1 OrionMRQ™ nasal drug and vaccine delivery device. Zeteo's latest innovative delivery device provides pharmaceutical and biotech companies developing drugs, peptides, proteins, monoclonal antibodies and vaccines with precise, metered unit dose systemic delivery via the nasal route.

Nasal administration provides needle free, rapid systemic uptake into the body via the nose. Nasal delivery of vaccines can invoke a fast local immune response in the respiratory track, which is frequently the primary route of infection for contagious pathogens such as pandemic flu or coronavirus. The ZEOx1 OrionMRQ™ device is intuitive to use, enabling either patient self-administration or administration by caregivers with configurations available for both adults and children.

The OrionMRQ reloadable nasal delivery device has the capability to store up to four unit doses in the on-board storage compartment. The device is compact making it easy to carry in a pocket or purse. Zeteo intranasal delivery devices incorporate novel packaging technology utilizing a Form Fill Seal (FFS) flexible foil, packaging the drug or vaccine in a unit dose blister reducing the cost and eliminating the supply chain constraints of glass vials.

ZEOx1™ blister packaging provides exceptional barrier properties to protect the drug or vaccine during storage and transport and can be stored at room temperature, refrigerated or frozen storage conditions. The ZEOx1™ packaging technology is commercially scalable to produce millions of doses per day; a critically important requirement for rapid, cost effective deployment of vaccines and medical countermeasures to global populations.

About Zeteo Biomedical LLC:

Zeteo Biomedical™ is a biomedical device technology company based in Austin, Texas. Zeteo provides patient-centric delivery device technology, drug/device combination product development services and fill/finish packaging technology for pharmaceuticals, biopharmaceuticals, biologics and botanicals for intranasal, nose-to-brain, ophthalmic, sublingual, and animal care product applications.

For more information, please visit the Zeteo website at: https://www.zeteobiomed.com/

Related link: https://www.zeteobiomed.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Drugs and Pharmaceuticals, Free News Articles

Oral Vaccine Boosts COVID Immunity: study conducted on nonhuman primates is published in the journal Vaccine

ROCHESTER, Minn. -- Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced results confirming the activity of an oral vaccine formulation for boosting immunity against SARS-CoV-2. The full study conducted on nonhuman primates is published in the journal Vaccine accessible at http: https://www.sciencedirect.com/science/article/pii/S0264410X21016716

The article describes the evaluation of an oral COVID-19 vaccine built on the vesicular stomatitis virus (VSV) platform. Oral administration of the VSV based vaccine induced antibodies that could neutralize SARS-CoV-2, the virus that causes COVID-19. More importantly, the novel oral formulation powerfully boosted the levels of neutralizing antibodies against SARS-COV-2 in previously vaccinated monkeys. The oral vaccine was shown to be safe and did not cause clinically significant adverse effects.

"By tweaking the way we generate the VSV-SARS vaccine, we created a new oral formulation that worked remarkably well to boost virus neutralizing antibody titers when administered into the cheek pouches of cynomolgus macaques whose immunity was waning after they had been primed with an intramuscular vaccine," stated Kah-Whye Peng, Ph.D., Chief Technical Officer of Vyriad, and first author of this publication. "Oral dosing is convenient and more likely to be accepted by people who are reluctant to receive yet another intramuscular injection to boost their immunity."

The COVID-19 pandemic is not over and there is a continued need to deliver vaccines to a much of the world's population. An effective oral vaccine/booster has the potential to dramatically improve vaccine uptake rates by addressing some of the key barriers to effective deployment such as logistics of distribution to remote populations, fear of needles, and administration to young children.

"We are excited by these groundbreaking findings. Vyriad has cGMP manufacturing capabilities and is running clinical trials using an engineered VSV for cancer therapy. We are therefore actively seeking partnership to help bring this promising platform to human testing," stated Stephen J Russell, M.D., Ph.D., Chief Executive Officer of Vyriad.

The publication is a collaboration between researchers at Vyriad, Imanis Life Sciences, Regeneron Pharmaceuticals, and the University of Minnesota.

About Vyriad, Inc.

Vyriad is a clinical-stage company developing virus-based therapeutics, focusing initially on proprietary oncolytic virus therapies for the treatment of cancers with significant unmet needs. Founded by scientists at Mayo Clinic and the University of Miami, Vyriad is working with VSV, measles and picornavirus platforms, programming their viruses to selectively attack cancer cells, thereby igniting antitumor immune responses that can complete the process of tumor destruction and prevent disease recurrence.

Our lead platform, derived from vesicular stomatitis virus (VSV), is being evaluated in ongoing Phase 1-2 clinical trials addressing multiple cancer types. Vyriad and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have a well-established broad-based strategic agreement for the discovery and development of new oncolytic virus treatments for cancer leveraging Vyriad's VSV platform and Regeneron's PD-1 inhibitor Libtayo® (cemiplimab-rwic) as well as its unmatched antibody discovery capabilities. Vyriad is a privately held company based in Rochester, Minnesota.

For more information, visit https://vyriad.com/.

Related link: https://vyriad.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Alliances and Partnerships, Business, Drugs and Pharmaceuticals, Free News Articles

Myrio Therapeutics and Pure MHC, LLC Announce Research Collaboration to Develop Novel, Targeted Antibody-Based Cancer Therapies

OKLAHOMA CITY, Okla. -- Pure MHC, LLC and Myrio Therapeutics Pty Ltd (Myrio) today announced a collaboration to develop new antibody-based oncology therapeutics. The companies will combine Pure MHC's proprietary offering of MHC peptide targets for oncology with Myrio's revolutionary Retained Display(tm) (ReD) antibody discovery process to initially create up to three novel therapies based on targets distinct to tumors across multiple types of cancer.

The cancer therapies resulting from this collaboration will represent a unique synergism: Myrio's ReD platform is differentiated in its ability to routinely identify antibodies that bind to peptides from intracellular proteins presented on the cell surface by major histocompatibility complex (MHC), and Pure MHC is a world-leader in the identification and validation of peptide/MHC (pMHC) targets. Antibodies to next generation pMHC oncology targets may provide more efficacious therapies, particularly for solid tumors, while minimizing off-target effects for patients.

Researchers at both companies expressed excitement at the prospect of combining these innovative approaches:

"The speed and flexibility of Myrio's ReD platform enables the generation of robust antibody-based therapies against challenging targets like pMHC with high affinity and specificity," said Myrio's CEO Pete Smith. "Pure MHC's curated pMHC targets are an excellent fit for our platform and substantially de-risk downstream development."

Pure MHC's Chief Scientist, William Hildebrand, PhD shared this enthusiasm, "Pure MHC is dedicated to the identification of pMHC complexes distinct to cancer and absent from healthy tissues. Peptide/MHC complexes for several oncology indications have been identified by Pure MHC as present on tumors yet absent from healthy tissue, and we are excited for Myrio to deploy their cutting-edge technology to engineer antibodies that recognize our targets with great specificity."

From a business perspective, these therapeutic candidates will bolster Myrio's existing portfolio of in-house assets while providing Pure MHC access to a powerful antibody platform that enables multiple therapeutic pipelines.

"Myrio's platform is not just an outstanding scientific fit, the collaboration represents a unique and exciting way for Pure MHC to deploy its novel target assets strategically," said Kris Looney, President of Pure MHC. "As we continue to provide targets from our pipeline to the market via more traditional partner licensing models, we felt the time was right to also establish our own therapeutic pipeline and have found exactly the collaborator we need in Myrio."

Pete Smith agreed, "With the close alignment of both scientific and business objectives between our two companies, a partnership between Myrio and Pure MHC just makes so much sense. We are excited about its potential."

The companies expect the collaboration to yield therapeutic candidates within the next twelve months.

About Myrio Therapeutics

Myrio Therapeutics is driving a new frontier of antibody-based therapies as the company's Retained Display(tm) (ReD) antibody platform offers identification of highly specific human antibodies that bind to peptide-MHC complexes. Myrio's antibodies can readily be converted into multispecific, CAR-T or other formats, dramatically increasing the target landscape for these modalities. Visit: http://www.myriotx.com/

About Pure MHC

Pure MHC, LLC is a platform technology company funded and managed by Emergent Technologies, Inc. with expertise in disease-specific target identification and validation as well as immunotherapeutic drug development for cancer, infectious disease, and autoimmune diseases. The Pure MHC target discovery technology was developed by Chief Scientist William Hildebrand, Ph.D., of the University of Oklahoma Health Science Center. For more information, visit: https://puremhc.com/

About Emergent Technologies

Emergent Technologies, Inc. is an innovation solutions and technology commercialization leader headquartered in Austin, Texas. Visit: http://www.etibio.com/

Related link: https://puremhc.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Drugs and Pharmaceuticals, Free News Articles, Product Launches, Software

Geminid Systems Unveils Pharmalite CRM to Boost Remote Engagement of Pharma Field Teams

REDWOOD CITY, Calif. -- Geminid Systems, Inc. today announced the global rollout of a SaaS super-app that aims to improve pharmaceutical operations by helping field teams easily overcome challenges arising from the ongoing COVID pandemic.

In conjunction with the product's worldwide release, subscriptions to the app are available at discounted pricing through Jan. 31, 2022.

"Pharmalite CRM is an all-in-one app that enables pharma sales and medical field teams to much more effectively perform, track, and analyze the complex tasks involved in working with existing and prospective healthcare providers," said Guru Karur, VP Product Strategy.

"It's essential for pharma companies," Karur continued, "to have field teams that can communicate better, faster, and more impactfully with providers by use of digital transformation technologies. Companies are finding it difficult now in this pandemic environment to meet patient needs, satisfy regulatory compliance requirements, and reach business objectives."

Karl Gunst, senior product lead, agreed. "The pandemic is making it difficult to build effective field teams. It's more difficult because the environment has changed from face-to-face to remote interactions. Existing solutions have failed to meet the new remote needs."

According to Karur, a potent attribute of Pharmalite CRM is its ability to create fully regulatory-compliant recordings and paper-trails for each interaction between the field teams and health care providers, whether remote or otherwise.

Gunst added that Pharmalite CRM eliminates the need to use as many as a dozen separate apps to cover all the bases. "Pharmalite CRM consolidates within a single app the functionalities to permit training, compliance, analytics, compensation, and more," he said.

"Most CRM solutions lack built-in analytics and advanced insights," Karur said. "Pharmalite CRM fills this gap with excellent support for startup, midlife, and fully mature pharmaceutical companies alike-especially those that urgently need to become more agile."

Pharmalite CRM was in development and beta testing for three years prior to today's debut, but the super-app already is in use by a number of pharmaceutical companies, Gunst revealed.

Company officials predict Pharmalite CRM will quickly emerge as a formidable rival to the industry's current top-selling CRM products.

Said Karur: "We in fact believe Pharmalite CRM will eventually overtake the competition as more and more pharmaceutical teams subscribe to our solution and discover its advanced capabilities and actionable AI-driven insights, which are made possible by highest compliance, performance, and scalability features."

To learn more about Pharmalite CRM, please visit https://www.pharmalitecrm.com/.

ABOUT GEMINID SYSTEMS

Redwood City, California-based Geminid Systems, Inc. is the maker of Pharmalite CRM, currently the only all-in-one pharma SaaS product with applications for sales, medical, market access, as well as management and executive teams. In developing Pharmalite CRM, Geminid harnessed mobile and web technologies to its extensive cloud technologies experience, thereby permitting creation of a fully integrated package of productivity-enhancing, process-simplifying tools designed for unparalleled ease of use.

Related link: https://geminidsystems.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Drugs and Pharmaceuticals, Free News Articles, Reports and Studies

iCell Gene Therapeutics Announces cCAR-T Clinical Publication in the Stem Cell Reviews and Reports Journal

STONY BROOK, N.Y. -- iCell Gene Therapeutics, a clinical stage biopharmaceutical company focused on immunotherapies for hematologic malignancies, solid tumors, organ rejections and autoimmune disorders, today announced the publication of their clinical study utilizing cCAR T-cell immunotherapy to successfully treat a patient with lupus. Their CAR is directed against CD19 and BCMA surface proteins generating a cCAR with dual expression of CD19 and BCMA CAR molecules. Their cCAR is one of a kind in the family of engineered CAR T-cells researchers are studying.

Their report "Treatment of Systemic Lupus Erythematosus Using BCMA-CD19 Compound CAR" published on August 30, 2021, shows the clinical success of cCAR in treating a patient with Systemic Lupus Erythematosus (SLE).

According to Dr. Yupo Ma, founder of iCell Gene Therapeutics, "After a single infusion of CD19-BCMA cCAR the patient achieved undetectable levels of autoantibodies that mediate SLE, successfully treating the patient's SLE for 2 years without the need for additional medications."

The publication is available online at https://doi.org/10.1007/s12015-021-10251-6.

About SLE

Systemic lupus erythematosus (SLE) is an antibody-mediated autoimmune disease, in which autoantibodies attack its own tissues, resulting in widespread tissue damage in the affected organs including kidneys, lungs, joints, brain and blood vessels. According to the Lupus Foundation of America, it estimates that 1.5 million Americans, and at least five million people worldwide, have a form of lupus.

About CD19-BCMA cCAR Therapy

iCell has developed a novel compound Chimeric Antigen Receptor (cCAR)approach. In this approach, the cCAR T cells express two distinct and fully functional CAR molecules, one that targets the molecule CD19 present on B cells and one that targets BCMA, which is present on plasma cells. In their recently published paper, researchers have shown that this cCAR led to rapid and dramatic decreases in B cell levels and levels of "autoantibodies" (antibodies that attack the body's own cells) in a patient with SLE.

As B cells are part of the normal immune system, it is preferable that the elimination of B cells be temporary. After 9 months of B cell depletion, the patient's B cells returned to normal. Importantly, the levels of autoantibodies remained undetectable. Based on these results, the researchers concluded that cCAR effectively "reset" the antibody-producing populations. In this "reset," the problematic cell populations were removed, leaving behind a fresh, clean slate. From this, new B cells and plasma cells were eventually formed, which did not have the same autoantibody-producing properties. Because of this, the patient has not had further lupus symptoms despite receiving no additional medications for over 2 years.

Given the prevalence of antibody-mediated disorders, this cCAR may prove useful for a variety of different medical conditions.

Sjögren's Syndrome, autoimmune hemolytic anemia, neuromyelitis optica spectrum disorder, celiac disease, type 1 diabetes, inflammatory bowel disease, rheumatoid arthritis, psoriasis, and multiple sclerosis all incorporate autoantibody formation in disease pathogenesis. Additionally, organ rejection following transplantation may be mediated by antibodies. By "resetting" the immune system prior to organ transplantation, this antibody-mediated rejection may be avoided. More research is needed on the long-term efficacy and safety of this treatment, but future applications of cCAR has a large window of opportunity.

About iCell Gene Therapeutics

iCell Gene Therapeutics, located in Stony Brook, New York, is a clinical-stage biopharmaceutical company developing first-in-class chimeric antigen receptor engineered cells. Their main focuses are on autoimmune disorders, AML, and T-cell malignancies. Their current clinical trials utilize their CARvac, T-cell targeted CARs, cCARs and non-gene edited universal CARs engineered as treatments for cancer, organ rejections and autoimmune diseases. These studies are ongoing in the US and China for their use.

For more information, please visit http://icellgene.com/

CONTACT:
Media and Investors
Kevin Pinz
Tel: (631) 538-6218
Kevin.pinz@icellgene.com

RELATED LINKS:

https://www.lupus.org/resources/how-many-people-have-lupus-in-the-united-states

https://www.lupus.org/resources/what-is-lupus

Related link: http://icellgene.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Books and Publishing, Business, Drugs and Pharmaceuticals, Free News Articles

Kalyagen Announces Release of Free eBook on How to Optimize Health Using Stem Cells

AUSTIN, Texas -- Kalyagen® has announced the release and availability of a free eBook, "The Stemregen Effect - Tapping into the Power of Your Own Stem Cells," which provides an overview of how stem cells are the body's repair system and how STEMREGEN®, a natural stem cell enhancer, has been documented to increase the number of circulating stem cells by stimulating Endogenous Stem Cell Mobilization (ESCM).

"Supporting stem cell physiology is a new paradigm in health and wellness," said Christian Drapeau, CEO and Chief Scientist of Kalyagen®. "The latest scientific evidence indicates that this may very well be the best strategy to assist the body in regaining and maintaining optimal health."

The link between a lower number of circulating stem cells and the development of age-related diseases has been well-studied with numerous degenerative conditions, including diabetes, cardiovascular diseases, atherosclerosis, Alzheimer's disease, rheumatoid arthritis, pulmonary diseases, erectile dysfunction, and kidney disease. Increasing the number of circulating stem cells has been documented to enhance tissue repair or improve the course of disease formation in cases of acute myocardial infarction and many other degenerative conditions.

"Kalyagen has been inundated with questions regarding the stem cell repair system and how STEMREGEN naturally helps the body to release stems cells," said Herbert Dogan, CMO of Kalyagen®. "We are pleased to announce the release of our new publication which helps to answer all of these questions."

The eBook is available for download for free at https://www.kalyagen.com/the-stemregen-effect/.

STEMREGEN® is a unique and patent-pending blend of proprietary plant-based extracts documented to support ESCM and increase the number of circulating stem cells, supporting the natural ability of the body to repair and stay healthy. Ingredients in STEMREGEN® have been investigated in more than eight clinical studies for their effect on stem cell function, of which five were randomized, double- blind, placebo-controlled human clinical trials. STEMREGEN® has wide application in antiaging and overall health maintenance.

About Kalyagen

Kalyagen® was founded by Christian Drapeau, author of the bestseller Cracking the Stem Cell Code. Kalyagen® is a leader in the research and development of natural products aimed at supporting stem cell function of the body. Stem cells constitute the natural repair system of the body, and stem cell enhancers have been documented to strongly contribute to improving health and quality of life. STEMREGEN® is the first product developed by Kalyagen®. STEMREGEN® is a unique blend of proprietary plant-based extracts documented to support Endogenous Stem Cell Mobilization and provide other health benefits.

For more information, please visit our Website: https://www.kalyagen.com/

MEDIA CONTACT:

Biomics, LLC (dba Kalyagen®)

Herbert Dogan, Chief Marketing Officer (310-433-8072), hgd@kalyagen.com

Social media: @kalyagen #stemthetideoftime #stemthetide #thestemregeneffect

Disclaimer: None of the statements contained in this press release have been evaluated by the U.S. Food and Drug Administration. The products and information in the release are not intended to diagnose, treat, cure or prevent any disease.

Related link: https://www.kalyagen.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Drugs and Pharmaceuticals, Free News Articles, NonProfit and Charities

Live-Online C. diff. Symposium developed to support and guide patients, families, and caregivers through a C. difficile illness

TAMPA, Fla. -- The C Diff Foundation will host a free, live-online, and interactive symposium on Friday, July 16, 2021, from 1 to 3 p.m. EDT. Sponsored by Seres Therapeutics, the event is designed for patients who are being treated for a C. diff. infection (CDI) in addition to those who are recovering or who have experienced CDI recurrences. The patients, family members, and caregivers will all benefit from the information and up-to-date data presented.

Presenters are among some of the top C diff. thought leaders and include healthcare professionals, practitioners, and educators who are helping to change the way individuals maneuver through a C. difficile infection, worldwide.

Unlike other presentations on this topic, C. diff. Survivors will share their C. diff. infection journeys to provide a real-world perspective on the patient experience. Other topics addressed will include creating a culture for patient-centered care, C. diff. innovations, diagnostics, research, environmental safety, clinical trials, and studies, C diff. in pediatric patients and more.

To register for this global live-online event, visit: https://cdifffoundation.org/patient-family-caregiver-symposium-july-16-2021/

About Clostridioides difficile Infection (CDI)

Clostridioides (formerly Clostridium) difficile, also known as C. difficile, C. diff., is one of the most common cause and leading healthcare-associated infection in U.S. hospitals (Lessa, et al, 2015, New England Journal of Medicine). Recent estimates suggest C. difficile approaches 500,000 infections annually in the United States and is associated with approximately 20,000 deaths. (Guh, 2020, New England Journal of Medicine). Based on internal estimates including a recurrence rate of approximately 20 percent, the C Diff Foundation believes that the annual incidence in the U.S. approaches 600,000.

About Seres Therapeutics

Seres Therapeutics is a late-clinical stage biotechnology company with a strong development pipeline and rigorous scientific underpinning, working to revolutionize treatment of a wide range of diseases by modulating the function of the human microbiome.

It reported positive, topline results from the pivotal Phase 3 ECOSPOR III study evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile infection (CDI).

For more information: https://www.serestherapeutics.com/

About the C Diff Foundation

C Diff Foundation, a 501(c)(3) nonprofit, is the leading patient and healthcare organization educating and advocating for C. difficile (Clostridioides difficile, C. diff., CDI, CDAD) prevention, treatments, clinical trials, diagnostics, support, and environmental safety worldwide. Their Mission continues to move forward and grow through research conducted by government, industry, and academia strengthening the advocacy on behalf of patients, families, caregivers, healthcare professionals, and researchers worldwide.

For more information: https://cdifffoundation.org/

Follow C Diff Foundation:

Twitter @cdiffFoundation #cdiffpatientfamilycaregiver #cdiff2021 #cdiffwalks2021

C Diff Foundation(TM) is a trademark of the C Diff Foundation, established 2012 in the U.S.

Related link: https://cdifffoundation.org/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Drugs and Pharmaceuticals, Free News Articles, Product Launches

Pure MHC, LLC Announces Launch of its Peptide HLA Immunotherapy Data Resource following Collaboration with LifeNet Health

AUSTIN, Texas -- Pure MHC, LLC, a target discovery and development company, today announced the launch of its Peptide HLA Immunotherapy Data Resource ("PHIDR"), built through its collaboration with a trusted provider of transplant solutions and a leader in regenerative medicine, LifeNet Health.

The PHIDR healthy tissue database and repository will guide T Cell Receptor (TCR)-based immune therapy development to disease-specific targets by enabling developers to identify HLA/peptide complex targets found on healthy tissues. By screening potential target candidates against PHIDR, developers can confidently select, qualify, and focus efforts on those biomarker targets that minimize off-target or bystander effects.

The PHIDR database is representative of the full healthy human immunopeptidome as it includes HLA/peptide complexes expressed on multiple tissue samples from all over the body, with a focus on the vital organs. In addition to the peptide database, PHIDR includes a repository of matched cryopreserved tissue samples that enable complimentary orthogonal target validation techniques, including proteomics-based target quantification, genomics, and transcriptomics, on an as-needed basis.

For nearly 40 years, LifeNet Health has advanced medicine through the life-changing power of organ and tissue donation. Thanks to selfless donors, scientific discovery is advanced.

LifeNet Health LifeSciences has accelerated preclinical research and discovery through its growing portfolio of primary human cells and biospecimens for solutions that expedite research and allow the scientific community to develop and enhance new, safe therapies and medical breakthroughs.

"We are excited to offer access to the PHIDR database and repository to collaborators through our Pure MHC Solutions contract research arm," said Pure MHC President Kris Looney. "We could not have successfully built this resource without our collaborators at LifeNet Health. To be able to develop such a valuable resource for therapeutic development aligns nicely with LifeNet Health's mission to help patients live longer, healthier, and enjoy more active lives."

"We are proud to partner with Pure MHC and congratulate them on achieving success in their research efforts. Thanks to selfless donors, LifeNet Health is able to offer partners more than 40 types of biospecimens for research with over 200 protocols in place to meet the individual needs of researchers advancing scientific discovery," said Louis Dias, Vice President and General Manager of LifeNet Health LifeSciences. "The LifeNet Health LifeSciences team provides access to rare patient disease populations and enables researchers to unlock discoveries faster and with greater precision - offering the hope of new therapies to patients in need."

About Pure MHC

Pure MHC, LLC is a platform technology company funded and managed by Emergent Technologies, Inc. with expertise in disease-specific target identification and validation as well as immunotherapeutic drug development for cancer, infectious and autoimmune diseases and allergy. The Pure MHC target discovery technology was developed by Chief Scientist William Hildebrand, Ph.D., of the University of Oklahoma Health Sciences Center. Visit: www.puremhc.com

About LifeNet Health LifeSciences

LifeNet Health LifeSciences is an innovative leader, trusted collaborator, and reliable solutions provider - committed to advancing science, accelerating discovery, and optimizing outcomes. Leading the way in human in vitro biology, LifeSciences' game-changing innovations, currently under development, include models for the metabolic disease and oncology therapeutic areas and their related tools. For more information, go to www.LNHLifeSciences.org.

About Emergent Technologies

Emergent Technologies, Inc. is an innovation solutions and technology commercialization leader headquartered in Austin, Texas. Visit: www.etibio.com

Related link: https://puremhc.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Alliances and Partnerships, Business, Drugs and Pharmaceuticals, Free News Articles, Surgery and Neurotechnology

Pure Transplant Solutions Announces Collaboration with the University of Alabama at Birmingham to Develop Memory B Cell-Directed Diagnostics for HLA-Sensitized Patients

BIRMINGHAM, Ala. -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with The University of Alabama at Birmingham (UAB), a leading institution in transplant research, to develop a new class of transplant diagnostics aimed at the detection and identification of HLA-specific memory B cells which are poised to produce HLA-specific immunoglobulin injurious to transplanted grafts.

The research is being led by Dr. Frances Lund, Charles H. McCauley Professor and Chair Department of Microbiology, Dr. John Killian, resident in the Department of Surgery, and Dr. Rico Buchli, VP of Products and Services at PTS, and focuses on using PTS's newly created Class I and Class II biotinylated soluble HLA (sHLA) proteins to understand the breadth and specificity of HLA-reactive B cells in sensitized individuals. These proprietary HLA molecules can be utilized in standard flow cytometry workflows for easy processing and analysis that the parties hope will provide a new tool for clinicians and researchers to use when caring for transplant patients.

Almost all previous work on HLA sensitized individuals has relied upon assays that detect circulating anti-HLA antibodies. The goal is to determine the reactivities of HLA-reactive B cells in these sensitized patients and compare these reactivities to those that are present among circulating anti-HLA antibodies. Using panels of biotinylated HLA molecules in combination with various tetramerized fluorescent reagents allows the interrogation of the specific B cell receptors expressed by HLA-reactive B cells.

"Prevention of B cell activation and proliferation is crucial for the survival of a transplant patient. For patient monitoring, identifying the right approach to immune profiling at each stage of clinical development-including the later stages, when it is often considered impractical to include these approaches-may be critical for identifying predictors of rejection responses, or monitoring immunosuppression efficacy", said Dr. Buchli. "Flow cytometric analysis using our fluorescent tagged HLA products have the capabilities needed to meet the increased demands to detect, identify, and monitor HLA-specific memory B cells."

"Our research at the University of Alabama at Birmingham seeks to improve the success of organ transplants," said John Killian, Jr., M.D., a research resident in the UAB Department of Surgery. "One problem is that following pregnancy or transplant, patients form antibodies against non-self HLA molecules. These antibodies comprise a major barrier to transplantation, and they exacerbate gender and racial disparities for thousands of people who await a life-saving transplant. Thus, we want to understand the breadth and specificity of HLA-reactive memory B cells in sensitized women. Pure Protein's extensive selection of recombinant HLA molecules will be integral to our projects, allowing us to pair fluorescence-activated cell sorting of HLA-reactive B cells with subsequent analysis of recombinant-antibody specificities. An improved understanding of the phenotype and specificity of HLA-reactive B cells will offer new opportunities to diagnose and treat HLA sensitization."

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, LLC was founded in 1999 in order to leverage the leading research in HLA protein of parent company, Pure Protein, LLC, into solutions to address a growing list of needs in organ transplantation. Visit: www.puretransplant.com

About Pure Protein, LLC

Pure Protein, LLC is a biotechnology company funded and managed by Emergent Technologies, Inc. that is focused on the development and commercialization of proprietary technologies related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma. Pure Protein, in conjunction with its affiliates and subsidiaries, aims to bring novel therapies and diagnostic tools to patients across a wide range of application areas spanning from therapeutic development in the fields of oncology, autoimmunity, and infectious disease, to antibody mediated rejection in transplantation.

Through its new ecommerce website, http://www.hlaprotein.com/, Pure Protein now offers academic and commercial researchers the ability to purchase individual HLA reagents to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aide in improving the design of vaccination and therapeutic targeting strategies.

About the University of Alabama Birmingham

Known for its innovative and interdisciplinary approach to education at both the graduate and undergraduate levels, the University of Alabama at Birmingham, a part of the University of Alabama System, is an internationally renowned research university and academic medical center with over $600 million in research awards annually, as well as Alabama's largest employer, with some 23,000 employees, and has an annual economic impact exceeding $7 billion on the state. The pillars of UAB's mission include education, research, innovation and economic development, community engagement, and patient care. Learn more at https://www.uab.edu/.

Related link: https://www.puretransplant.com/

This news story was published by the Neotrope® News Network - all rights reserved.